Pain RSS Page 12

Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 479 results found since Jan 2013.

Novel Cancer Therapeutics and Implications for Rehabilitation
AbstractPurpose of ReviewTo determine how the more recently developed cancer treatments may impact patient function. To determine how rehabilitation medicine may assist in improving quality of life in cancer survivors being treated with novel cancer therapeutics.Recent FindingsChimeric antigen receptor-T cell therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, immune checkpoint inhibitors, and cancer-specific vaccines are more recently developed anti-neoplastic treatments that are positively affecting survivorship curves. These treatments come with unique toxicity profiles including pain, neurologic im...
Source: Current Physical Medicine and Rehabilitation Reports - October 23, 2021 Category: Rehabilitation Source Type: research

He Was Shot by a Stranger but Treated Like a Criminal When He Reached the ER
When Greg Jackson Jr. thinks about the night he was shot, the most painful part of the memory isn’t that he almost died. It’s not the six surgeries he underwent, the half-year bedridden, or the image of his younger cousin using a shirt as a tourniquet to save his life. It’s not even the thought of the gunman. What brings on a flood of resentment is his reception at the hospital. After he was rolled off the ambulance on a stretcher, still clad in his bloody clothes, police officers—not doctors or nurses—greeted him and began peppering him with questions. Where was he when the shots rang out? W...
Source: TIME: Health - October 13, 2021 Category: Consumer Health News Authors: Melissa Chan Tags: Uncategorized COVID-19 Guns Health Care healthscienceclimate nationpod Source Type: news

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy
CONCLUSION: The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.PMID:34634986 | DOI:10.1080/07357907.2021.1992420
Source: Cancer Investigation - October 12, 2021 Category: Cancer & Oncology Authors: Mona Ariamanesh Pejman Porouhan Babak PeyroShabany Danial Fazilat-Panah Mansoureh Dehghani Maryam Nabavifard Farbod Hatami Mohammad Fereidouni James S Welsh Seyed Alireza Javadinia Source Type: research

Microneedle system: A modulated approach for penetration enhancement
Drug Dev Ind Pharm. 2021 Oct 11:1-35. doi: 10.1080/03639045.2021.1992421. Online ahead of print.ABSTRACTThe microneedles show advantages over transdermal drug delivery systems on account of better skin permeation bypassing the stratum corneum. To increase the flux of permeation, penetration enhancement techniques like physical and chemical methods are combined with a trans-epidermal delivery system across the skin causing minimal pain. These techniques include iontophoresis, sonophoresis, and electroporation for physical enhancement of drug delivery via topical route by either disrupting the structure of the stratum corneu...
Source: Drug Development and Industrial Pharmacy - October 12, 2021 Category: Drugs & Pharmacology Authors: Nirupma Khare Pravin Shende Source Type: research

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Brief Report: Tolerability of COVID-19 Vaccines, BNT162b2 and mRNA-1273, in Patients with Thymic Epithelial Tumors
CONCLUSIONS: Tolerability of COVID-19 mRNA vaccines in patients with TETs is comparable to the general population. Most patients with pre-existing AD did not experience disease flares and the development of new AD was rare. Patients with TETs should be encouraged to get vaccinated against COVID-19 due to the documented benefits of vaccination and manageable risk profile.PMID:34514444 | PMC:PMC8423742 | DOI:10.1016/j.jtocrr.2021.100229
Source: Clinical Lung Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Madison Ballman Shannon Swift Cristina Mullenix Yvonne Mallory Chen Zhao Eva Szabo Meenakshi Shelat Susan Sansone Seth M Steinberg Meredith J McAdams Arun Rajan Source Type: research

I Didn ’t Want to Push My Aunt to Get the Vaccine. Now I Live With Regrets
In normal times, the ICU is a dreadful place. Sickness lingers like a fog. You can feel it, sense it, even hear it—the machinery pumping, the alarms ringing, the nurses scrambling. In pandemic times, the ICU is chilling. Death lives here. Medical staff members wear green biohazard suits, face shields, latex gloves and shoe coverings. Strips of red tape—“ISOLATION,” they read—mark the windows and doors of individual rooms. Behind each is a patient who cannot breathe on their own, kept alive by a ventilation machine that is connected to an invasive tube running down their windpipe and into the l...
Source: TIME: Health - September 12, 2021 Category: Consumer Health News Authors: Ross Dellenger Tags: Uncategorized Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20